Kodiak Sciences (KOD) stock was up on Wednesday alongside updated analyst coverage following the clinical-stage biopharmaceutical company’s latest earnings report. Let’s dig into that below:
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
- Five-star H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and a $58 price target for KOD stock, suggesting a possible 35.99% upside for the shares.
- Five-star LifeSci Capital analyst Patrick Dolezal maintained a Buy rating and a $70 price target for KOD stock, implying a possible 64.13% upside for the shares.
The bullish coverage of Kodiak Sciences stock followed an incredible earnings report from the company. Kodiak Sciences reported advancements in several clinical trials during the quarter, including top-line results in its GLOW2 Phase 3 study. It also revealed positive progress in its Phase 3 DAYBREAK, Phase 3 PEAK, and Phase 3 PINNACLE studies.
In addition to strong study progress, Kodiak Sciences said that it has enough cash on hand to continue operations into 2027. This provides the company with the runway it needs to continue the advancement of its pipeline and potentially commercialize its treatments, which would allow it to be more than just a clinical-stage biopharmaceutical company.
Kodiak Sciences Stock Movement Today
Kodiak Sciences stock was up 12.33% on Wednesday, extending a 52.11% year-to-date rally. The stock has also climbed 1,327.72% over the past 12 months.
With today’s news came heavy trading of KOD stock, as more than 1 million shares changed hands. For comparison, the company’s three-month average daily trading volume is about 660,000 shares.
Is Kodiak Sciences Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Kodiak Sciences is Strong Buy, based on six Buy ratings over the past three months. With that comes an average KOD stock price target of $66, representing a potential 54.53% upside for the shares.
